<DOC>
	<DOCNO>NCT00192478</DOCNO>
	<brief_summary>MEDI-524 give 5 dos 3 15 mg/kg high-risk child appear safe well tolerate .</brief_summary>
	<brief_title>Open-Label , Dose-Escalation Study 2 5 IM Doses MEDI-524 3 mg/kg 15 mg/kg ; Children Followed 90 Days After Their Last Dose MEDI-524</brief_title>
	<detailed_description>This study design describe safety , tolerability , immunogenicity , pharmacokinetics escalate , repeat IM injection ( intend route administration immunoprophylaxis ) MEDI-524 , initially child £6 month old history prematurity ( ³32 £35 week gestation , without BPD ) , one target population infant high risk serious RSV disease .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>All male female child must meet follow criterion : [ Groups 1 , 2 , 3 ] The child must bear ³32 £35 week gestation £6 month age time entry study ( child must enter 6month birthday ) [ Group 3 ] The child must £24 month age time entry study ( child must enter 24month birthday ) diagnose BPD , stable decreasing dos diuretic , steroid , bronchodilator within previous 6 month The child must general good health time entry The child 's parent legal guardian must provide write informed consent ; The child must able complete followup visit 90 day follow last injection MEDI524 Parent/legal guardian patient must available telephone access Children must none following : Hospitalization time study entry ( unless discharge expect within 3 day entry study ) [ All child Groups 1 2 ; child £6 month age Group 3 ] Birth hospitalization &gt; 6 week duration [ Only child &gt; 6 month age Group 3 ] Birth hospitalization &gt; 12 week duration Been receive chronic oxygen therapy mechanical ventilation time study entry ( include CPAP ) [ Groups 1 2 ] Diagnosis BPD , define history prematurity associate chronic lung disease oxygen requirement &gt; 28 day Congenital heart disease ( CHD ) ( Children medically surgically correct [ close ] patent ductus arteriosus CHD may enrol ) Evidence infection hepatitis A , B , C virus Known renal impairment , hepatic dysfunction , chronic seizure disorder , immunodeficiency HIV infection Mother know HIV infection Any follow laboratory finding blood obtain within 7 day prior study entry : BUN creatinine &gt; 1.5´ upper limit normal age ; AST ( SGOT ) ALT ( SGPT ) &gt; 1.5´ upper limit normal age ; hemoglobin &lt; 9.5 gm/dL ; white blood cell count &lt; 4,000 cells/mm3 ; platelet count &lt; 120,000 cells/mm3 Acute illness progressive clinical disorder Active infection , include acute RSV infection Previous reaction IGIV , blood product , foreign protein Have ever receive palivizumab Received within past 120 day currently receive immunoglobulin product ( RSVIGIV [ RespiGamÒ ] , IVIG ) , investigational agent Currently participate investigational study Previously participate investigational study RSV vaccines monoclonal antibody .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>